Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 738 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Cancer in My Community: Obstacles to Caring for People With Cancer... November 23, 2020 FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma October 27, 2025 ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... April 16, 2015 5 ways cancer can impact sexual wellbeing May 17, 2023 Load more HOT NEWS Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation... Ending smoking could more than halve England’s cancer inequality gap Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... Experimental Medulloblastoma Treatment Gets a Boost with Nanoparticles
